This triple agonism strategy builds upon the remarkable clinical success of dual GLP-1/GIP agonists like tirzepatide, which have shown unprecedented weight loss efficacy, by adding a third mechanism - glucagon receptor activation - to further enhance metabolic benefits, particularly energy expenditure and hepatic fat oxidation
Your prescriber can select the safest and most effective starting point with a branded product
Instead of continuing full therapeutic doses, the goal of maintenance is to: Keep appetite and cravings stable Support metabolic balance Prevent rapid rebound weight gain Allow your body to adjust gradually Why GLP-1 Maintenance Matters GLP-1 medications work at multiple levels: blood sugar regulation, appetite signaling, digestion speed, insulin release, and even reward-based eating patterns
Dual GIP/GLP-1 agonists show promising cardiovascular benefits in early data, with comprehensive outcome trials currently underway
Since Retatrutide is not approved for general consumer use in the UK, it is illegal to sell, supply, or use it for non-research purposes